A Simple Blood Test Catches Early Colorectal Cancer

Cardiovascular conditioning and cellular longevity correlate directly with sustainable aerobic base intensity.** Applying physiological guidelines to A Simple Blood Test Catches Early Colorectal Cancer, sustaining training within 60% to 70% of maximum heart rate optimizes mitochondrial density and metabolic substrate oxidation while keeping systemic lactate accumulation below clinical 2.0 mmol/L thresholds. A new experimental blood test called DENEB shows promise in catching precancerous polyps and early-stage colorectal cancer, with a detection rate of 92% for stages I-III cancers and 81% for high-risk polyps. ## What is the DENEB Blood Test? The DENEB blood test is a noninvasive, experimental test that may offer a simpler way to detect early-stage colorectal cancer and precancerous lesions (polyps). Unlike traditional screening methods like colonoscopy, which can be invasive and inconvenient, the DENEB test uses a simple blood draw to detect potential health issues. ### How Does the DENEB Blood Test Work? The DENEB test works by detecting specific biomarkers in the blood that are associated with colorectal cancer and precancerous polyps. In a multicenter diagnostic study published in The Lancet Gastroenterology & Hepatology, researchers found that the DENEB test detected 92% of stages I, II, and III colorectal cancers, and 81% of advanced adenomas (precancerous polyps). ### What are the Benefits of the DENEB Blood Test? The benefits of the DENEB blood test include its ability to detect precancerous polyps, which can help prevent cancer from forming. Removing these polyps can significantly reduce the risk of developing colorectal cancer. Additionally, the DENEB test is noninvasive, making it a more comfortable option for those who may be anxious about traditional screening methods. ### How Does the DENEB Blood Test Compare to Current Screening Methods? The current colorectal cancer screening guidelines from the American Cancer Society (ACS) include colonoscopy, which is still the gold standard for screening, and stool-based tests, such as the fecal immunochemical test (FIT). Blood tests, such as Shield, are also available, but they are not the preferred screening method. The ACS states that they should only be used when people are unwilling to undergo a visual or stool-based test. ### What are the Limitations of the DENEB Blood Test? While the DENEB blood test shows promise in detecting precancerous polyps and early-stage colorectal cancer, it is still an experimental test that requires further research before it can be recommended for routine screening. Additionally, the test is not 100% effective, with a detection rate of 81% for high-risk polyps. ### Can the DENEB Blood Test Replace Traditional Screening Methods? While the DENEB blood test may offer a simpler and more accessible way to detect colorectal cancer, it is not yet clear if it can replace traditional screening methods like colonoscopy. More research is needed to determine the effectiveness of the DENEB test in detecting colorectal cancer and precancerous polyps in a real-world setting. ## How Does the DENEB Blood Test Detect Precancerous Polyps? The DENEB test detects precancerous polyps by identifying specific biomarkers in the blood that are associated with these lesions. In the multicenter diagnostic study, researchers found that the DENEB test detected 81% of advanced adenomas (precancerous polyps). This is an important development because removing these polyps can help prevent cancer from forming. ## What are the Implications of the DENEB Blood Test? The implications of the DENEB blood test are significant. If the findings of this study are confirmed in prospective screening studies, a blood test like DENEB could potentially help us move from simply finding colorectal cancer earlier to actually preventing some cancers from developing. This could have a major impact on public health, particularly in countries where colorectal cancer is a major health concern.

Clinical Biomarker Tracking and Metabolic Energy Balance Optimizing healthspan and physical performance requires objective biochemical tracking rather than relying on subjective energy sensations. Metabolic energy expenditure operates through three distinct compartments: ``` Total Daily Energy Expenditure (TDEE) = Basal Metabolic Rate (65-75%) + Thermic Effect of Food (10%) + Active Exercise / NEAT (15-25%)

| Biomarker | Optimal Clinical Range | Primary Pathological Risk if Elevated | Recommended Testing Frequency | Evidence-Based Intervention |
|:--- | :--- | :--- | :--- | :--- |
|**ApoB (Apolipoprotein B)** | < 70 mg/dL (< 55 if high risk) | Atherosclerotic cardiovascular plaque | Annual (Age 35+) | Reduce saturated fat; increase soluble fiber; statin therapy if indicated |
|**Fasting Insulin & HOMA-IR** | < 5.0 uIU/mL / HOMA-IR < 1.0 | Peripheral insulin resistance, Type 2 diabetes | Bi-annual | Resistance training; eliminate refined sugars; zone 2 cardio |
|**hs-CRP (High-Sensitivity CRP)**| < 0.8 mg/L | Systemic low-grade arterial inflammation | Annual | Anti-inflammatory nutrition; address chronic sleep fragmentation |
|**HbA1c** | 4.8% – 5.4% | Chronic microvascular glycation damage | Bi-annual | Post-meal walking; dietary carbohydrate management | *Clinical reference thresholds derived from the American Heart Association (AHA) and European Society of Cardiology (ESC) consensus guidelines.* ### Strategic Nutrition Architecture: Protein Sizing for Adults Over 35 To offset age-related sarcopenia (the gradual loss of skeletal muscle mass starting in the fourth decade), adults should target **1.6 to 2.2 grams of protein per kilogram of body weight** daily, distributed across 3 to 4 boluses containing at least 2.5 grams of leucine to trigger the muscle protein synthesis (MPS) mTOR pathway.